false
0001701541
0001701541
2023-12-13
2023-12-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
The UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 13, 2023
BLACK DIAMOND THERAPEUTICS, INC.
(Exact name of registrant as specified in its
charter)
|
|
|
Delaware |
001-39200 |
81-4254660 |
(State or other jurisdiction |
(Commission |
(I.R.S. Employer |
of incorporation) |
File Number) |
Identification No.) |
One
Main Street, 14th Floor |
|
|
Cambridge, Massachusetts |
|
02141 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
(617) 252-0848
(Registrant’s telephone number, including
area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which
registered |
Common Stock, $0.0001 par value per share |
BDTX |
The Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
| Item 7.01. | Regulation FD Disclosure. |
On December 13, 2023, Black Diamond
Therapeutics, Inc. (the “Company”) issued a press release titled “Black Diamond Announces Topline Results
from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM.” A copy of the press release is furnished as
Exhibit 99.1 to this Current Report on Form 8-K.
The information in Item 7.01 of this Current Report
on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities
of that section, nor shall they be deemed incorporated by reference into any filing by the Company under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
On December 13, 2023, the Company announced
topline results from the dose escalation portion of the Phase 1 clinical trial of BDTX-1535 in patients with recurrent glioblastoma (“GBM”)
who expressed epidermal growth factor receptor (“EGFR”) alterations at the time of their initial diagnosis.
Phase 1 Dose Escalation Clinical Trial
Topline Results in Patients with Recurrent GBM
Clinical data as of November 2023 reflect 27 patients with recurrent
GBM who received a range of doses spanning 15 mg to 400 mg once daily (“QD”) in the dose escalation cohort. No new safety
signals were observed, and adverse events were consistent with the EGFR tyrosine kinase inhibitor class of drugs, including primarily
Grade 1 and 2 diarrhea and rash. Patients with non-small cell lung cancer dosed at 100 mg QD or greater demonstrated confirmed partial
responses in lung lesions and central nervous system metastases.
Key enrollment and inclusion factors:
| · | Of the 27 patients with recurrent GBM, 22 were started at or escalated to a dose of 100 mg QD or greater
and reached at least one post baseline tumor assessment. |
| · | Patients were heavily pretreated, with a median of two prior lines of therapy (range of one to
four). All patients except one had received prior temozolomide. Other prior treatments included chemotherapy, bevacizumab,
checkpoint inhibitors or investigational agents. |
| · | Patients were required to have EGFR alterations at the time of diagnosis, but EGFR status was not known
at time of treatment with BDTX-1535 as biopsies are not commonly performed for recurrent disease. |
Key results:
| · | Of the 22 patients evaluable for efficacy, three patients were on therapy longer than ten months,
one patient longer than six months, and five patients longer than four months. Historical progression-free survival in this
population is in the range of two to four months. |
| · | The patient on therapy the longest remains on BDTX-1535 at 100 mg QD for over fifteen months with
prolonged disease stabilization. This patient had previously progressed after three months of temozolomide treatment. |
| · | Of the 19 patients with measurable disease by Response Assessment in Neuro-Oncology criteria, one patient
achieved a confirmed partial response and eight patients experienced stable disease. The patient with the confirmed partial response stayed
on treatment for longer than four months at 200 mg QD. |
The Company plans to
submit results from the dose escalation GBM cohort for presentation at a medical meeting in the second quarter of 2024.
Forward-Looking Statements
Statements contained in this Current Report on
Form 8-K regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially
from those expressed or implied by such forward looking statements. Such statements include, but are not limited to, the continued development
and advancement of BDTX-1535, including the Phase 1 clinical trial and the expected timing for presentation of the full BDTX-1535 dose
escalation data in GBM, and the potential of BDTX-1535 to benefit patients with GBM in an earlier line of treatment. In some cases, you
can identify forward-looking statements by terminology such as “believe,” “estimate,” “intend,” “may,”
“plan,” “potentially,” “will,” “expect,” “enable,” “likely” or
the negative of these terms or other similar expressions. Any forward-looking statements in this Current Report on Form 8-K are based
on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute
to the uncertain nature of the forward-looking statements include those risks and uncertainties set forth in the Company’s Annual
Report on Form 10-K for the year ended December 31, 2022, filed with the United States Securities and Exchange Commission and
in its subsequent filings filed with the United States Securities and Exchange Commission. All forward-looking statements contained in
this Current Report on Form 8-K speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the date on which they were made.
Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
BLACK DIAMOND THERAPEUTICS, INC. |
|
|
|
|
|
|
Date: December 13, 2023 |
By: |
/s/ Brent Hatzis-Schoch |
|
Name: |
Brent Hatzis-Schoch |
|
Title: |
Chief Operating Officer and General Counsel |
Exhibit 99.1
Black Diamond Therapeutics Announces Topline
Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM
Initial results show promising clinical activity
in heavily pretreated patients
22 patients evaluable for efficacy: 3 patients
on therapy longer than 10 months, 1 patient longer than 6 months, and 5 patients longer than 4 months
19 patients with measurable disease by RANO
criteria: 1 patient with confirmed partial response and 8 patients with stable disease
BDTX-1535 generally well tolerated, consistent
with prior disclosures and no new safety signals observed
“Window of opportunity” trial enrolling
patients to assess PK in brain tissue
CAMBRIDGE, Mass.,
December 13, 2023 (GLOBE NEWSWIRE) – Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company
developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced
topline results from the dose escalation portion of the Phase 1 clinical trial of BDTX-1535 in patients with recurrent glioblastoma (GBM)
who expressed epidermal growth factor receptor (EGFR) alterations at the time of their initial diagnosis. BDTX-1535, a fourth-generation,
brain-penetrant, covalent EGFR inhibitor, is under investigation in a Phase 1 clinical trial for the treatment of patients with non-small
cell lung cancer (NSCLC) or GBM.
“These initial results in patients with
recurrent GBM are encouraging, as there are no approved therapies available for those who progress following initial treatment, and there
is strong rationale for a brain penetrant, covalent EGFR inhibitor such as BDTX-1535 to have a meaningful impact in earlier lines of therapy,”
said Patrick Wen, M.D., Director of The Center for Neuro-Oncology at Dana-Farber Cancer Institute.
Clinical data as
of November 2023 reflect 27 patients with recurrent GBM who received a range of doses spanning 15mg to 400mg once daily (QD) in
the dose escalation cohort. Combined pharmacokinetic (PK) and safety data from these 27 patients with GBM and 27 patients with NSCLC
were previously presented on October 14, 2023 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer
Therapeutics. No new safety signals were observed; adverse events were consistent with the EGFR tyrosine kinase inhibitor (TKIs) class
of drugs, including primarily Grade 1 and 2 diarrhea and rash. Patients with NSCLC dosed at 100mg QD or greater demonstrated confirmed
partial responses in lung lesions and CNS metastases.
Key enrollment and inclusion factors
| · | Of the 27 patients with recurrent GBM, 22 were started at or escalated to a dose of 100mg QD or greater
and reached at least one post baseline tumor assessment. |
| · | Patients were heavily pretreated, with a median of 2 prior lines of therapy (range 1-4). All patients
except one had received prior temozolomide. Other prior treatments included chemotherapy, bevacizumab, checkpoint inhibitors or investigational
agents. |
| · | Patients were required to have EGFR alterations at the time of diagnosis, but EGFR status was not known
at time of treatment with BDTX-1535 as biopsies are not commonly performed for recurrent disease. |
Key results
| · | Of the 22 patients evaluable for efficacy, 3 patients were on therapy longer than 10 months, 1
patient longer than 6 months, and 5 patients longer than 4 months. Historical progression-free survival (PFS) in this population is in
the range of 2-4 months. |
| · | The patient on therapy the longest remains on BDTX-1535 at 100mg QD for over 15 months with prolonged
disease stabilization. This patient had previously progressed after 3 months of temozolomide treatment. |
| · | Of the 19 patients with measurable disease by Response Assessment
in Neuro-Oncology (RANO) criteria, 1 patient achieved a confirmed partial response (PR) and 8 patients experienced stable disease
(SD). The patient with the PR stayed on treatment for longer than 4 months at 200 mg QD. |
Black Diamond plans
to submit results from the dose escalation GBM cohort for presentation at a medical meeting in the second quarter of 2024. Enrollment
is ongoing in a “window of opportunity” clinical trial of BDTX-1535 in second-line patients with high-grade glioma. The trial
(NCT06072586) is sponsored by the Ivy Brain Tumor Center in Phoenix, Arizona and is enrolling patients prior to a planned resection
in order to assess PK and pharmacodynamics (PD) in brain tissue. Patients achieving adequate drug levels in the gadolinium non-enhancing
regions of the tumor will continue with treatment following surgery. The trial will enroll up to 22 patients, and clinical data is expected
in the second quarter of 2024.
“We believe the ‘window of opportunity’
trial of BDTX-1535 will provide valuable information on both drug levels in the brain and clinical activity in second-line patients, and
will inform potential next steps in our development program,” said Sergey Yurasov, M.D., Ph.D., Chief Medical Officer of Black Diamond
Therapeutics. “More than half of all newly diagnosed GBM patients express an altered form of EGFR, and preclinical data demonstrate
BDTX-1535 potently inhibits this spectrum of alterations. Therefore, BDTX-1535 may be optimally suited to benefit first-line patients.”
About BDTX-1535
BDTX-1535 is an
oral, brain-penetrant MasterKey inhibitor of oncogenic epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer
(NSCLC), including families of non-classical driver mutations (e.g., L747P, L718Q), acquired resistance C797S mutation, and complex
mutations. BDTX-1535 is a fourth generation TKI that potently inhibits, based on preclinical data, more than 50 oncogenic EGFR mutations
expressed across a diverse group of patients with NSCLC in multiple lines of therapy. Based on preclinical data, BDTX-1535 also inhibits
EGFR extracellular domain mutations and alterations commonly expressed in glioblastoma (GBM) and avoids paradoxical activation observed
with earlier generation reversible TKIs. Dose escalation of BDTX-1535 in patients with GBM is complete and dose expansion is currently
ongoing in patients with NSCLC (NCT05256290).
About Black Diamond Therapeutics
Black Diamond Therapeutics
is a clinical-stage oncology company focused on the development of MasterKey therapies that address families of oncogenic mutations in
clinically validated targets. The Company’s MasterKey therapies are designed to address broad genetically defined patient populations,
overcome resistance, minimize wild-type mediated toxicities, and be brain-penetrant to treat CNS disease. The Company is advancing two
clinical stage programs: BDTX-1535, a brain-penetrant fourth-generation EGFR MasterKey inhibitor targeting EGFR mutant NSCLC and GBM,
and BDTX-4933, a brain penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. For more information,
please visit www.blackdiamondtherapeutics.com.
Forward-Looking Statements
Statements contained in this press release
regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding: the continued development and advancement of BDTX-1535,
including the Phase 1 clinical trial, the expected timing for clinical updates on data from the “window of opportunity”
clinical trial of BDTX-1535 in recurrent GBM patients and presentation of the full BDTX-1535 dose escalation data in GBM, and the
potential of BDTX-1535 to benefit patients with GBM in an earlier line of treatment. Any forward-looking statements in this
statement are based on management’s current expectations of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such
forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include those risks and
uncertainties set forth in its Annual Report on Form 10-K for the year ended December 31, 2022, filed with the United
States Securities and Exchange Commission and in its subsequent filings filed with the United States Securities and Exchange
Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. The
Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date
on which they were made.
Contacts
For Investors:
Mario Corso, Head of Investor Relations, Black Diamond Therapeutics
mcorso@bdtx.com
For Media:
media@bdtx.com
v3.23.3
Cover
|
Dec. 13, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Dec. 13, 2023
|
Entity File Number |
001-39200
|
Entity Registrant Name |
BLACK DIAMOND THERAPEUTICS, INC.
|
Entity Central Index Key |
0001701541
|
Entity Tax Identification Number |
81-4254660
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
One
Main Street, 14th Floor
|
Entity Address, City or Town |
Cambridge
|
Entity Address, State or Province |
MA
|
Entity Address, Postal Zip Code |
02141
|
City Area Code |
617
|
Local Phone Number |
252-0848
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, $0.0001 par value per share
|
Trading Symbol |
BDTX
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Black Diamond Therapeutics (NASDAQ:BDTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Black Diamond Therapeutics (NASDAQ:BDTX)
Historical Stock Chart
From Apr 2023 to Apr 2024